光动力疗法的抗肿瘤机制研究进展

doi:10.3969/j.issn.1004-616x.2014.05.018

摘要/Abstract

摘要：

光动力作用是指由光敏剂介导，在光的作用下，使机体细胞或生物分子发生功能或形态变化，累积而致细胞的损伤和坏死，又称光敏化－氧化作用。光动力疗法(PDT)是利用光敏剂介导的光动力作用进行疾病诊断和治疗的技术，由于光敏剂选择性地在肿瘤部位高浓度积聚，在激光照射下杀伤肿瘤细胞，目前PDT在临床上主要被用于治疗恶性实体瘤，也可用于一些癌前病变的治疗以及肿瘤诊断。本文对光动力疗法的特点以及抗肿瘤机制的研究进展做一综述。

关键词: 光敏剂, 光动力疗法, 作用机制, 抗肿瘤

林铌，包捷，王爱平. 光动力疗法的抗肿瘤机制研究进展[J]. 癌变·畸变·突变, doi: 10.3969/j.issn.1004-616x.2014.05.018.

参考文献

[1] Emma S，Nyman，Paavo H. Hynninen. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy[J]. J Photochem Photobiol B，2004，73(1/2)：1-28.

[2] Erdogmus A，Nyokong，T. Synthesis of zinc phthalocyanine derivatives with improved photophysicochemical properties in aqueous media[J]. J Mol Struct，2010，977(1/2/3)：26-38.

[3] Ackroyd R，Kelty C，Brwn N，et al. The history of photodetection and photodynamic therapy [J]. Photochem Photobiol，2001，74(5)：656-669.

[4] 丁新民，徐勤枝，顾瑛，等. 光动力学治疗肿瘤的简史和现状[J]. 中国肿瘤，2003，12(3)：151-155.

[5] 董晓曦. 激光治疗仪的功率密度测量系统[D]. 天津：天津医科大学，2011.

[6] Overton G，Anderson GS，Belforte AD，et al. Reviews and forecasts for 2009-2010 global laser market[J]. Laser Focus World Chin，2010，1( 1) ：8-14．

[7] 杨琛. 光动力治疗药物合成进展[J]. 广州化工，2012，40(12)： 52-54.

[8] Sanfilippo NJ，Hsi A，DeNittis AS，et al. Toxicity of photodynamic therapy after combined external beam radiotherapy and intraluminal brachytherapy for carcinoma of the upper aerodigestive tract[J]. Lasers Surg Me，2001，28(3)： 278-281.

[9] Xu R，Wang Q. Toward creation of a cancer drug toxicity knowledge base：automatically extracting cancer drug-side effect relationships from the literature[J]. Am Med Inform Assoc，2013，21(1) ：90-96.

[10] Ochsner M. Photodynamic therapy：the clinical perspective. Review on applications for control of diverse timorous and non-tumorous diverses[J]. Arzneinittel Forschung，1997，47(11)： 1185-1194.

[11] 张林，虞乐华. 光动力疗法作用机制的研究进展[J]. 激光杂志，2003，24(2)：91-93.

[12] Hopper C. Photodynamic therapy：A clinical reality in the treatment of cancer[J]. Lancet Oncol，2000，1(4) ：212-219.

[13] Xu P，Chen J，Chen Z，et al. Receptor targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity[J]. PLoS One，2012，7(5)：37051.

[14] Tran GD，Sun XD，Abnet CC，et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trail cohort in China[J]. Int J Cancer，2005， 113(3)：456-463.

[15] Lehmann P. Side effects of topical photodynamic therapy[J]. Hautarzt，2007，58(7)：597-603.

[16] Larson DM，Cunningham BB. Photodynamic therapy in a teenage girl with xeroderma pigmentosum type C[J]. Pediatr Dermatol，2012，29(3)：373-374.

[17] Wiegell SR，Fabricius S，Gniadecka M. Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp：a randomized multicentre study[J]. Br J Dermatol，2012，166(6)：1327-1332.

[18] Wagner M，Suarez ER，Theodoro，TR. Methylene blue photodynamic therapy in malignant melanoma decreases expression of proliferating cell nuclear antigen and heparanases [J]. Clin Exp Dermatol，2012，37(5)：527-533.

[19] Zheng Y，Le V，Cheng Z. Development of rapid and highly sensitive HSPA1A promoter-driven luciferase reporter system for assessing oxidative stress associated with low-dose photodynamic therapy[J]. Cell Stress Chaperones，2013， 18(2)：203-213.

[20] Ahn JC，Chung PS. The activity of G-ROS and the predominant role of Type II reaction in the photodynamic therapy using 9-hydroxypheophorbide-alpha for HeLa cell lines[J]. Gen Physiol Biophys，2012，31(3)：343-350.

[21] Oleinick NL，Evans HH. The photodynamic therapy：cellular targets and mechanism[J]. Radiat Res，1998，150(5)：146-156.

[22] Engbrecht BW，Wenon C，Kachur AV，et al. Photofin-mediated photodynamic therapy induced vascular occlusion and apoptosis in a human sarcoma xenograft model[J]. Cancer Res，1999，59(17)：4334-4342.

[23] Halkiotis K，Yova D，Pantelias G. In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy[J]. Mutagenesis，1999，14(2)：193-198.

[24] 戴维德，王雷，刘凡光，等. 应用激光扫描共聚焦显微成像术研究光敏剂亚细胞定位[J]. 中国激光医学杂志，2004，13(1)： 12-17.

[25] Mori M，Kuroda T，Obana A，et al. In vitro plasma protein binding and cellular uptake of ATX-S10(Na)，a hydrophilic chlorin photosensitizer[J]. Jpn J Cancer Res，2000，91(8)： 845-852.

[26] 汲振余，范天黎，赵立群，等. 光敏剂PpIX亚细胞分布方式对食管癌细胞光动力学效应的影响[J]. 世界华人消化杂志，2009， 17(16)：1602-1608.

[27] Chiu SM，Oleinick NL. Dissociation of mitochondyial depolarization from cytochrome c crelease during apoptosis induced by photodynamic therapy[J]. Br J Cancer，2001 Apr20；84(8)：1099-1106.

[28] Jér?me B，Richard D，Michel J. Killing efficacy of a new silicon phthalocyanine in human melanoma cells treated with photodynamic therapy by early activation of mitochondrion-mediated apoptosis[J]. Exp Dermatol，2004， 13(1)：33-44.

[29] Song-mao Chiu，Liang-yan Xue，Minh Lam，et al. A requirement for bid for induction of apoptosis by photodynamic therapy with a lysosome- but not a mitochondrion-targeted photosensitizer[J]. Photochem Photobiol，2010，86(5)： 1161-1173.

[30] 陈靖京，王玉茂，刘天军. 新型卟啉类光敏药物介导的PDT对两种胃癌细胞HGC27和MGC803的杀伤效应[J]. 国际生物医学工程杂志，2011，34(3)：1673-4181.

[31] Jiangwei Tian，Lin Ding，Hai-Jun Xu. Cell-specific and pH-activatable rubyrin-loaded nanoparticles for highly selective near-infrared photodynamic therapy against cancer[J]. J Am Chem Soc，2013，135(50)：18850–18858.

[32] Lei Liu，Xianwang Wang，Hui Li. Involvement of BimL activation in apoptosis induced by lysosomal photodamage[C] // Seventh International Conference on Photonics and Imaging in Biology and Medicine：7280，Wuhan，China：Proc. SPIE， 2009，7028(1A) ，doi：10.1117/12.82256.

[33] 刘镭，张真真. 实时监测溶酶体光损伤诱导细胞凋亡过程中Bax定位的时空变化[J]. 激光生物学报，2013，22(3)：210-213.

[34] 曹良启，薛平，陈育宾，等. 光动力抑制胆管癌QBC939细胞生长的实验研究[J]. 中华普通外科学文献，2011，5(1)：21-24.

[35] 姜智换，史蕤，李超，等. 华卟啉钠介导的光动力疗法在体外和体内对肿瘤生长的抑制作用[J]. 癌变·畸变·突变，2013，25(3)：163-167.

[36] Mitsunaga M，Ogawa M，Kosaka N. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules[J]. Nat Med，2011，17(12)：1685-1691.

[37] Schagen FH，Moor AC，Cheong SC，et al. Photodynamic treatment of adenoviral vectors with visible light：an easy and convenient method for viral inactivation[J]. Gene Ther，1999， 6(5)：873-881.

[38] Gomer CJ. Preclinical examination of first and second generation photosensitizers used in photodynamic therapy[J]. Photochem Photobiol，1991，4(6)：1093-1107.

[39] Henderson BW，Waldow SM，Mang TS，et al. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy[J]. Cancer Res，1999，45：572-576.

[40] Webber J，Herman M，Kessel D，et al. Photodynamic treatment of neoplastic lesions of the gastrointestinal tract[J]. Langenbecks Arch Surg，2000，385(4)：299-304.

[41] McMahon KS，Wieman TJ，Moore PH，et al. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction，vessel leakage，andtumor response[J]. Cancer Res，1994，54(3)：5374-5379.

[42] Korbelik M，Dougherty GJ. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors[J]. Cancer Res，1999，59(8)：1941-1946.

[43] Korbelik M，Krosl G，Krosl J，et al. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy[J]. Cancer Res，1996，56(24)：5647-5652.

[44] Gollnick SO，Vaughan L，Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy[J]. Cancer Res，2002，62(6)：1604-1608.

[45] Mroz P，Szokalska A，Wu MX，et al. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response[J]. PLoS One，2010，5(12)：e15194.

[46] Latkowski B. Use of sensitizers and photo laser for diagnosis and treatment of malignant tumors[J]. Otolaryngol Pol，1995， 49(20)：205-208.

[47] Jin CS，Zheng G. Liposomal nanostructures for photosensitizer delivery[J]. Lasers Surg Med，2011，43(7)：734-748.